Gemcitabine and Oxaliplatin in Advanced Gall Bladder Carcinoma
Authors/Creators
- 1. Senior Resident, Department of Radiotherapy, Comprehensive Cancer Care Clinic, NMCH, Patna, Bihar
- 2. Associate Professor, Department of Radiotherapy, Comprehensive Cancer Care Clinic, NMCH, Patna, Bihar
Description
Background: Gall Bladder Carcinoma (GBC), an uncommon and aggressive malignancy, is typically detected at a late stage and has a poor prognosis. The usual treatment is gemcitabine and cisplatin, but novel combina-tions like GEMoX, which combines gemcitabine and oxaliplatin, are being tested. This experiment examined GEMOX’s safety and efficacy in advanced GBC. Methods: A retrospective study examined 200 NMCH Patna patients who received GEMOX for advanced GBC between April 2022 and April 2024. The GEMOX regimen consisted of six cycles per 21 days, each involving 1000 mg/m² gemcitabine on Days 1 and 8 and 85 mg/m² oxaliplatin on Day 1. Adverse effects, response rates, PFS, and OS were assessed. Data from medical records was evaluated using SPSS or R. Results: Progress-free survival was 4.5 months (95% CI: 4.0-5.0) and overall survival was 8.7 months (95% CI: 7.9-9.5). Only 5% of patients fully recovered, 35% improved, 40% did not change, and 20% worsened. Stabilisation was 80% and disease control 40%. Most adverse effects were mild to moderate, including 30% neutropenia, 40% nausea/vomiting, and 25% peripheral neuropathy. Patients changed dosage 20% of the time and stopped taking medicine 10% of the time. Conclusion: With acceptable toxicity, GEMOX improves survival in advanced GBC patients. This treatment works well when surgical excision is not possible.
Abstract (English)
Background: Gall Bladder Carcinoma (GBC), an uncommon and aggressive malignancy, is typically detected at a late stage and has a poor prognosis. The usual treatment is gemcitabine and cisplatin, but novel combina-tions like GEMoX, which combines gemcitabine and oxaliplatin, are being tested. This experiment examined GEMOX’s safety and efficacy in advanced GBC. Methods: A retrospective study examined 200 NMCH Patna patients who received GEMOX for advanced GBC between April 2022 and April 2024. The GEMOX regimen consisted of six cycles per 21 days, each involving 1000 mg/m² gemcitabine on Days 1 and 8 and 85 mg/m² oxaliplatin on Day 1. Adverse effects, response rates, PFS, and OS were assessed. Data from medical records was evaluated using SPSS or R. Results: Progress-free survival was 4.5 months (95% CI: 4.0-5.0) and overall survival was 8.7 months (95% CI: 7.9-9.5). Only 5% of patients fully recovered, 35% improved, 40% did not change, and 20% worsened. Stabilisation was 80% and disease control 40%. Most adverse effects were mild to moderate, including 30% neutropenia, 40% nausea/vomiting, and 25% peripheral neuropathy. Patients changed dosage 20% of the time and stopped taking medicine 10% of the time. Conclusion: With acceptable toxicity, GEMOX improves survival in advanced GBC patients. This treatment works well when surgical excision is not possible.
Files
IJPCR,Vol16,Issue12,Article213.pdf
Files
(484.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:848741e952ed2f2540ad26d7b0d22fe1
|
484.6 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-11-26
Software
- Repository URL
- http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue12,Article213.pdf
- Development Status
- Active
References
- 1. A. Sharma, B. K. Mohanti, S. P. Chaudhary, V. Sreenivas, R. K. Sahoo, N. K. Shukla, et al., "Modified gemcitabine and oxaliplatin or gemcitabine+ cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial," Eur. J. Cancer, vol. 123, pp. 162-170, 2019.2. H. Lagenfelt, H. Blomstrand, and N. O. Elander, "Real-world evidence on palliative gemcitabine and oxaliplatin (GemOx) combination chemotherapy in advanced biliary tract cancer," Cancers, vol. 13, no. 14, p. 3507, 2021. 3. A. Markussen, L. H. Jensen, L. V. Diness, and F. O. Larsen, "Treatment of patients with advanced biliary tract cancer with either oxaliplatin, gemcitabine, and capecitabine or cisplatin and gemcitabine—a randomized phase II trial," Cancers, vol. 12, no. 7, p. 1975, 2020. 4. T. O. Goetze, W. O. Bechstein, U. S. Bankstahl, T. Keck, A. Koenigsrainer, S. A. Lang, et al., "Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC)–a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/CALGP/ACO-GAIN-trial–," BMC Cancer, vol. 20, pp. 1-8, 2020. 5. J. Edeline, M. Benabdelghani, A. Bertaut, J. Watelet, P. Hammel, J. P. Joly, et al., "Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study," J. Clin. Oncol, vol. 37, no. 8, pp. 658-667, 2019. 6. S. T. Kim, J. H. Kang, J. Lee, H. W. Lee, S. Y. Oh, J. S. Jang, et al., "Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial," Ann. Oncol., vol. 30, no. 5, pp. 788-795, 2019. 7. X. Y. Cui, X. C. Li, J. J. Cui, X. S. Wu, L. Zou, X. L. Song, et al., "Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen," Hepatobiliary Surg. Nutr., vol. 10, no. 4, pp. 498-508, 2021. 8. N. Sturm, J. S. Schuhbaur, F. Hüttner, L. Perkhofer, and T. J. Ettrich, "Gallbladder cancer: current multimodality treatment concepts and future directions," Cancers, vol. 14, no. 22, p. 5580, 2022. 9. A. A. Azizi, A. Lamarca, M. G. McNamara, and J. W. Valle, "Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis," Crit. Rev. Oncol. Hematol, vol. 163, p. 103328, 2021. 10. M. Javle, H. Zhao, and G. K. Abou-Alfa, "Systemic therapy for gallbladder cancer," Chin. Clin. Oncol, vol. 8, no. 4, p. 44, 2019. 11. Z. I. Hu and K. H. Lim, "Evolving paradigms in the systemic treatment of advanced gallbladder cancer: updates in year 2022," Cancers, vol. 14, no. 5, p. 1249, 2022. 12. X. Chen, X. Wu, H. Wu, Y. Gu, Y. Shao, Q. Shao, et al., "Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, openlabel, phase II trial," J. Immunother. Cancer, vol. 8, no. 2, 2020. 13. A. Vogel, P. Wenzel, G. Folprecht, P. Schütt, H. Wege, A. Kretzschmar, et al., "53MO NalIRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio-and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC–AIO-HEP-0116)," Ann. Oncol., vol. 33, pp. S563-S564, 2022. 14. X. Chen, S. Qin, S. Gu, Z. Ren, Z. Chen, J. Xiong, et al., "Camrelizumab plus oxaliplatin‐ based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial," Int. J. Cancer, vol. 149, no. 11, pp. 1944-1954, 2021. 15. M. Buyuksimsek, M. M. Kidi, A. Ogul, C. Mirili, and S. Paydas, "The effect of inflammatory markers on survival in advanced biliary tract carcinoma treated with gemcitabine/oxaliplatin regimen," J. Gastrointest. Cancer, vol. 52, pp. 249-255, 2021.